Latent atherogenic dyslipoproteinemia diagnostics by genetic analysis of monozygotic twins

Aim. To analyze intra-pair correlation of lipid-transport system parameters in fasting state and after food lipid load (FLL) in monozygotic twins (MT) with different body mass (BM), for identifying genetic and environmental factor role in atherogenic dyslipidemia development.
Material and methods. Nine pairs (n=18) of male and female MT aged 37-65 years were divided into two groups, by abdominal obesity (AO) presence (n=9) or absence (n=6). Three persons with gluteo-femoral obesity were excluded from the analysis. In all patients, standard FLL test was performed, with measurement of TCH, TG, HDL-CH, LDL-CH, apoAI, apoB, and their ratio, HDL components (CH, phospholipids, CH esters), and CH-acceptor HDL potential 3 and 6 hours after FLL test.
Results. In MT with or without AO, lipid and apoprotein LP parameters, as well as CH-acceptor HDL potential, were similar to those in previously examined large groups of patients with various obesity types. In MT with AO, small particles were more prevalent in sub-fraction HDL specter than in MT with normal BM. In MT, atherogenic LP parameters correlated with one another, including TCH, apoB, АТ (apoB/AI), LDL particle size in fasting state and after FLL. No correlation for fasting antiatherogenic HDL components was observed in MT. After FLL, HDL level and content, according to cell culture CH-acceptor HDL potential, began to correlate.
Conclusion. Lipid and apoprotein atherogenic LDL parameters in fasting state and after FLL were determined mostly by genetic factors. Levels and content of antiatherogenic HDL are mostly determined by environmental factors; their post-FLL dynamics is genetically determined.

1. Expert Panel on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults. Executive summary of the clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults. Arch Intern Med 1998; 158: 1855-67.

2. Haffher SM. Obesity and the metabolic syndrome: the San Antonio Heart Study. Br J Nutr 2000; 83(Suppl 1): 567-70.

3. Okosun IS, Liao Y, Rotimi CN, et al. Abdominal adiposity and clustering of multiple metabolic syndrome in White, Black and Hispanic Americans. Ann Epidemiol 2000; 10(5): 263-70.

4. Jeppesen J, Hein HO, Suadicani P, et al. Relation of high TG-low HDL cholesterol and LDL cholesterol to incidence of ischemic heart disease. An 8-year follow-up in the Copenhagen Male Study. Arterioscler Thromb Vasc Biol 1997; 17: 1114-20.

5. Оганов Р.Г., Перова Н.В., Метельская В.А. и др. Абдоминальное ожирение у больных артериальной гипертонией: атерогенные нарушения в системе транспорта липидов и обмена углеводов. РКЖ 2001; 31(5): 16-20.

6. Соколов Е.И., Озерова И.Н., Перова Н.В. и др. Снижение антиатерогенной значимости липопротеидов высокой плотности у лиц с ожирением. Кардиология 2004; 44(2): 45- 50.

7. Очерки близнецовых исследований (в клинической медицине). Под ред. Соколова Е.И., Гофман-Кадошникова П.Б., Лильина Е.Т. Москва «Медицина» 1980.

8. Гофман-Кадошников П.Б. Возможность вероятностной оценки диагноза зиготности, устанавливаемого методом подобия. Генетика 1973; 9(1): 156-61.

9. Гофман-Кадошников П.Б., Лильин Е.Т. Относительная оценка систем крови для диагностики зиготности близнецов и новый метод вычисления достоверности диагноза в свете теории информации. Генетика 1973; 9(8): 142-51.

10. Соколов Е.И., Александрович О.В., Щельцына Н.В. и др. Субфракционный спектр ЛПНП при абдоминальном и глютео-феморальном ожирении. Бюлл эксперим биол мед 2003; 11: 513-5.

11. Соколов Е.И., Горбачева О.И., Щукина Г.Н. и др. Липопротеиды сыворотки крови при различных типах ожирения в условиях жировой нагрузки. Клин мед 2004; 4: 25-9.

12. Patsch JR, Prasad S, Gotto AM, et al. HDL2: relationship of the plasma levels of this lipoprotein subspecies to its composition, to the magnitude of postprandial activities of lipoprotein lipase and hepatic lipase. J Clin Invest 1987; 80: 341-6.

13. Bucolo G. Quantitative determination of serum triglycerides by use of enzymes. Clin Chem 1973; 19: 476-81.

14. Roeschlau P, Berndt E, Gruber W. Enzymatische bestimmung des gesant cholesterines im serum. Z Klin Chem Klin Biochem 1974; 12: 226-9.

15. Assmann G, Schriewer H, Schmitz G, et al. Quantification of high-density-lipoprotein cholesterol by precipitation with phosphotungstic acid. Clin Chem 1983; 29: 2025-9.

16. Svanborg A, Svennerholm L. Plasma total lipid cholesterol, triglycerides, phospholipids and free fatty acids in a healthy Scandinavian population. Acta Med Scand 1961; 69: 43-6.

17. De la Llera Moya M, Atger V, Paul J, et al. A cell culture system for screening human serum for ability to promote cellular cholesterol efflux. Arterioscler Thromb 1994; 14: 1056-65.

18. Siemens H. The Diagnosis of identity of twins. J Hered 1927; 18: 201-9.